ArticleInternational journal of clinical and experimental medicine2015
TGF-β1 C-509T and T869C polymorphisms and cancer risk: a meta analysis.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.
- Pooled it
- Polymorphisms in IL-10 and TGF-β gene promoter are associated with lower risk to gastric cancer in a Mexican population.BMC cancer · 2019Article
- Genetic polymorphisms and gastric cancer risk: a comprehensive review synopsis from meta-analysis and genome-wide association studies.Cancer biology & medicine · 2019Article
- Association between TGF-β1 Polymorphisms and Head and Neck Cancer Risk: A Meta-Analysis.Frontiers in genetics · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledObjective The association between polymorphism of TGF-β1 and cancer risk has been discussed. Method A comprehensive electronic search was performed to identify articles published up until 12 December 2014 in Medline and Embase databases. The statistical analysis was performed by STATA 11.0 software and Review Manager 5.1 software.
resultsIn the present meta analysis, for C-509T (31 studies, 12944 cases and 15530 controls), no significant cancer risk was found in the overall analysis. In subgroup analysis, C-509T polymorphism was associated with decreased cancer risk in Asian population (OR=0.73 and 95% CI=0.59-0.90 for CT vs. CC), and there were no significant risks in gastric cancer, breast cancer, and other cancers. For T869C (11 studies, 2730 cases and 2973 controls), significantly increased risks of cancer were observed, and the ORs (95% CI) were 1.81 (1.18-2.78) for CC vs. TT, 1.50 (1.07-2.09) for TC vs. TT, 1.61 (1.13-2.30) for TC+CC vs. TT and 1.38 (1.11-1.73) for C-allele vs. T-allele, respectively. Subgroup analyses stratified by ethnicity and types of cancer were also performed, and the results indicated that T869C polymorphism was associated with cancer risk in Caucasion [1.93 (1.52-2.46) for TC vs. TT], but not in Asian [1.23 (0.80-1.90) for TC vs. TT]. We also observed that the T869C was associated with increased risk of squamous cell cancer of head and neck (SCCHN) [1.34 (1.07-1.67) for TC vs. TT]. Conclusion Decreased cancer risk association was observed in Asian for C-509T and significantly increased risk of cancer was observed for T869C.
Indexed as
Identifiers
26770387PMC4694287W2438687757What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.